{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:11:31Z","timestamp":1786979491272,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1007\/bf03343844","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T06:27:49Z","timestamp":1394519269000},"page":"199-203","source":"Crossref","is-referenced-by-count":46,"title":["Clinical application of 5\u03b1-reductase inhibitors"],"prefix":"10.1007","volume":"24","author":[{"given":"A.","family":"Cilotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Danza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,11]]},"reference":[{"key":"BF03343844_CR1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/0888-7543(91)90038-G","volume":"11","author":"EP Jenkins","year":"1991","unstructured":"Jenkins E.P., Hsieh C.L., Milatovich A., Normington K., Berman D.M., Francke U., Russell D.W. Characterization and chromosomal mapping of a human steroid 5\u03b1-reductase gene and pseudogene and mapping of the mouse homologue. Genomics 1991, 11: 1102\u20131112.","journal-title":"Genomics"},{"key":"BF03343844_CR2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1172\/JCI116665","volume":"92","author":"AE Thigpen","year":"1993","unstructured":"Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., Russell D.W. Tissue distribution and ontogeny of steroid 5\u03b1-reductase isozyme expression. J. Clin. Invest. 1993, 92: 903\u2013910.","journal-title":"J. Clin. Invest."},{"key":"BF03343844_CR3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<261::AID-PROS7>3.0.CO;2-E","volume":"629","author":"H Bonkhoff","year":"1996","unstructured":"Bonkhoff H., Stein U., Aumuller G., Remberger K. Differential expression of 5\u03b1-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 1996, 629: 261\u2013267.","journal-title":"Prostate"},{"key":"BF03343844_CR4","first-page":"1007","volume":"41","author":"C Boudon","year":"1995","unstructured":"Boudon C., Lobaccaro J.M., Lumbroso S., Lechevallier E., Mottet N., Gibelin B., Sultan C. 5\u03b1-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates effect of finasteride (Proscar), a 5\u03b1-reductase inhibitor. Cell. Mol. Biol. 1995, 41: 1007\u20131015.","journal-title":"Cell. Mol. Biol."},{"key":"BF03343844_CR5","first-page":"1361","volume":"81","author":"CM Smith","year":"1996","unstructured":"Smith C.M., Ballard S.A., Worman N., Buettner R., Masters J.R. 5\u03b1-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J. Clin. Endocrinol. Metab. 1996, 81: 1361\u20131366.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343844_CR6","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199210223271706","volume":"10","author":"AE Thigpen","year":"1992","unstructured":"Thigpen A.E., Davis D.L., Gautier T., Imperato- McGinley J., Russell D.W. Brief report: the molecular basis of steroid 5\u03b1-reductase deficiency in a large Dominican kindred. N. Engl. J. Med. 1992, 10: 1216\u20131219.","journal-title":"N. Engl. J. Med."},{"key":"BF03343844_CR7","first-page":"577","volume":"14","author":"JD Wilson","year":"1993","unstructured":"Wilson J.D., Griffin J.E., Russel D.W. Steroid 5\u03b1-reductase 2 deficiency. Endocr. Rev. 1993, 14: 577\u2013593.","journal-title":"Endocr. Rev."},{"key":"BF03343844_CR8","first-page":"3160","volume":"80","author":"MD Katz","year":"1995","unstructured":"Katz M.D., Cai L.Q., Zhu Y.S., Herrera C., DeFillo- Ricart M., Shackleton C.H, Imperato-McGinley J. The biochemical and phenotypic characterization of females homozygous for 5\u03b1-reductase-2 deficiency. J. Clin. Endocrinol. Metab. 1995, 80: 3160\u20133167.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343844_CR9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1365-2133.1999.03042.x","volume":"141","author":"EK Bayne","year":"1999","unstructured":"Bayne E.K., Flanagan J., Einstein M., Ayala J., Chang B., Azzolina B., Whiting D.A., Mumford R.A., Thiboutot D., Singer I.I., Harris G. Immunoistochemical localization of types 1 and 2 5\u03b1-reductase in human scalp. Br. J. Dermatol. 1999, 141: 481\u2013491.","journal-title":"Br. J. Dermatol."},{"key":"BF03343844_CR10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJM199401133300208","volume":"330","author":"RS Rittmaster","year":"1994","unstructured":"Rittmaster R.S. Finasteride. N. Engl. J. Med. 1994, 330: 120\u2013125.","journal-title":"N. Engl. J. Med."},{"key":"BF03343844_CR11","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1021\/jm00378a028","volume":"27","author":"GH Rasmusson","year":"1984","unstructured":"Rasmusson G.H., Reynolds G.F., Utne T., Jobson R.B., Primka R.L., Berman C., Brooks J.R. Azasteroids as inhibitors of rat prostatic 5\u03b1-reductase. J. Med. Chem. 1984, 27: 1690\u20131701.","journal-title":"J. Med. Chem."},{"key":"BF03343844_CR12","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1021\/jm00161a028","volume":"29","author":"GH Rasmusson","year":"1986","unstructured":"Rasmusson G.H., Reynolds G.F., Steinberg N.G., Walton E., Patel G.F., Liang T., Cascieri M.A., Cheung A.H., Brooks J.R., Berman C. Azasteroids: structure-activity relationships for inhibition of 5\u03b1-reductase and of androgen receptor binding. J. Med. Chem. 1986, 29: 2298\u20132315.","journal-title":"J. Med. Chem."},{"key":"BF03343844_CR13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2165\/00003088-199630010-00002","volume":"30","author":"JF Steiner","year":"1996","unstructured":"Steiner J.F. Clinical pharmacokinetics and pharmacodynamics of Finasteride. Clin. Pharmacokinet. 1996, 30: 16\u201327.","journal-title":"Clin. Pharmacokinet."},{"key":"BF03343844_CR14","first-page":"253","volume":"1","author":"E Palomino","year":"1999","unstructured":"Palomino E. GI-198745 Glaxo Welcome. Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs 1999, 1: 253.","journal-title":"Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs"},{"key":"BF03343844_CR15","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1021\/jm00078a022","volume":"36","author":"SV Frye","year":"1993","unstructured":"Frye S.V., Haffner C.D., Maloney P.R., Mook R.A. Jr, Dorsey G.F. Jr, Hiner R.N., Batchelor K.W., Bramson H.N., Stuart J.D., Schweiker S.L., et al. 6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5\u03b1-reductase. J. Med. Chem. 1993, 36: 4313\u20134315.","journal-title":"J. Med. Chem."},{"key":"BF03343844_CR16","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1021\/jm00041a014","volume":"37","author":"SV Frye","year":"1994","unstructured":"Frye S.V., Haffner C.D., Maloney P.R., Mook R.A., Jr, Dorsey G.F., Hiner R.N., Cribbs C.M., Wheeler T.N., Ray J.A., et al. 6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5\u03b1-reductase and human adrenal 3\u03b2-hydroxy-delta 5-steroid dehydrogenase\/ 3-keto-\u03b4 5-steroid isomerase. J. Med. Chem. 1994, 37: 2352\u20132360.","journal-title":"J. Med. Chem."},{"key":"BF03343844_CR17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1021\/jm960807v","volume":"40","author":"A Guarna","year":"1997","unstructured":"Guarna A., Belle C., Machetti F., Occhiato E.G., Payne A.H., Cassiani C., Comerci A., Danza G., De Bellis A., Dini S., Marrucci A., Serio M. 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5\u03b1-reductase 1 and 2. J. Med. Chem. 1997, 40: 1112\u20131129.","journal-title":"J. Med. Chem."},{"key":"BF03343844_CR18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1021\/jm00055a014","volume":"36","author":"CD Jones","year":"1993","unstructured":"Jones C.D., Audia J.E., Lawhorn D.E., McQuaid L.A., Neubauer B.L., Pike A.J., Pennington P.A., Stamm N.B., Toomey R.E., Hirsch K.S. Nonsteroidal inhibitors of human type 1 5\u03b1-reductase. J. Med. Chem. 1993, 36: 421\u2013423.","journal-title":"J. Med. Chem."},{"key":"BF03343844_CR19","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/S0960-894X(98)00505-8","volume":"8","author":"A Guarna","year":"1998","unstructured":"Guarna A., Occhiato E.G., Scarpi D., Tsai R., Danza G., Comerci A., Mancina R., Serio M. Synthesis of benzo[c]quinolizin-3-ones: selective non-steroidal inhibitors of steroid 5\u03b1-reductase 1. Bioorg. Med. Chem. Lett. 1998, 8: 2871\u20132876.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BF03343844_CR20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0960-894X(99)00698-8","volume":"10","author":"A Guarna","year":"2000","unstructured":"Guarna A., Occhiato E.G., Scarpi D., Zorn C., Danza G., Comerci A., Mancina R., Serio M. Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5\u03b1- reductase 1. Bioorg. Med. Chem. Lett. 2000, 10: 353\u2013356.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BF03343844_CR21","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0022-5347(17)37547-X","volume":"147","author":"E Stoner","year":"1992","unstructured":"Stoner E., Finasteride Study Group. The clinical effects of a 5a-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J. Urol. 1992, 147: 1298\u20131302.","journal-title":"J. Urol."},{"key":"BF03343844_CR22","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/jcem-71-6-1552","volume":"71","author":"J Geller","year":"1990","unstructured":"Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J. Clin. Endocrinol. Metab. 1990, 71: 1552\u20131555.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343844_CR23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","volume":"327","author":"GJ Gormley","year":"1992","unstructured":"Gormley G.J., Stoner E., Bruskewitz R.C., Imperato- McGinley J., Walsh P.C., McConnell J.D., Andriole G.L., Geller J., Bracken B.R., Tenover J.S., et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 1992, 327: 1185\u20131191.","journal-title":"N. Engl. J. Med."},{"key":"BF03343844_CR24","first-page":"C77","volume":"78","author":"M Serio","year":"1991","unstructured":"Serio M., Fiorelli G. Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 1991, 78: C77\u2013C81.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343844_CR25","first-page":"2576","volume":"85","author":"C Crescioli","year":"2000","unstructured":"Crescioli C., Maggi M., Vannelli G.B., Luconi M., Salerno R., Barni T., Gulisano M., Forti G., Serio M. Effect of vitamin D3 Analogue on Keratinocyte Growth factor induced cell proliferation in benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 2000, 85: 2576\u20132583.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343844_CR26","first-page":"703","volume":"79","author":"AL Dallob","year":"1994","unstructured":"Dallob A.L., Sadik N.S., Unger W., Lipert S., Geissler L.A., Gregoire S.L., Nguyen H.H., Moore E.L., Tanaka W.K. The effect of Finasteride, a 5\u03b1-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J.Clin. Endocrinol. Metab. 1994, 79: 703\u2013706.","journal-title":"J.Clin. Endocrinol. Metab."},{"key":"BF03343844_CR27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1523-1747.1998.00224.x","volume":"110","author":"JA Ellis","year":"1998","unstructured":"Ellis J.A., Stebbing M., Harrap S.B. Genetic analysis of male pattern baldness and 5\u03b1-reductase genes. J. Invest. Dermatol. 1998, 110: 849\u2013853.","journal-title":"J. Invest. Dermatol."},{"key":"BF03343844_CR28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","volume":"39","author":"KD Kaufman","year":"1998","unstructured":"Kaufman K.D., Olsen E.A., Whiting D., Savin R., DeVillez R., Bergfeld W., Price V.H., Van Neste D., Roberts J.L., Hordinsky M., Shapiro J., Binkowitz B., Gormley G.J. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J. Am. Acad. Dermatol. 1998, 39: 578\u2013589.","journal-title":"J. Am. Acad. Dermatol."},{"key":"BF03343844_CR29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0197-2456(94)00XXX-M","volume":"16","author":"P Feigl","year":"1995","unstructured":"Feigl P., Blumenstein B., Thompson I., Crowley J., Wolf M., Kramer B.S., Coltman C.A. Jr, Brawley O.W., Ford L.G. Design of the Prostate Cancer Prevention Trial (PCPT). Controlled Clin. Trials 1995, 16: 150\u2013163.","journal-title":"Controlled Clin. Trials"},{"key":"BF03343844_CR30","first-page":"223","volume":"80","author":"IL Wong","year":"1995","unstructured":"Wong I.L., Morris R.S., Chang L., Spahn M.A., Stanczyk F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 1995, 80: 223\u2013238.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343844_CR31","first-page":"89","volume":"85","author":"P Moghetti","year":"2000","unstructured":"Moghetti P., Tosi F., Tosti A., Negri C., Misciali C., Perrone F., Caputo M., Muggeo M., Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2000, 85: 89\u201394.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03343844_CR32","first-page":"1989","volume":"81","author":"C Mestayer","year":"1996","unstructured":"Mestayer C., Berthaut I., Portois M.C., Wright Kuttenn F., Mowszowicz I., Mauvais-Jarvis P. Predominant expression of 5 alpha-reductase type 1 in pubic skin from normal subjects and hirsute patients. J. Clin. Endocrinol. Metab. 1996, 81: 1989\u20131993.","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03343844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03343844\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03343844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T05:37:04Z","timestamp":1565242624000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03343844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["BF03343844"],"URL":"https:\/\/doi.org\/10.1007\/bf03343844","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}